It spreads through inhalation or contact with the fluids from an infected person's coughs or sneezes. 2 While often linked to ...

GSK’s NgG shot is based on generalised modules ... Germany, Spain, Brazil, the Philippines, and South Africa, with a readout expected in 2025. Meanwhile, some research has found that vaccines ...

Trump's tariffs could derail Europe's 2025 growth, say top Wall Street analysts. Goldman Sachs sees eurozone GDP at 0.7%, ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work with the University of Oxford on a cancer vaccine research program.

The University of Oxford and GSK are to work on a vaccine to target cells in the pre-cancerous stage (PA) Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to ...

GSK plc (LSE/NYSE: GSK), a global pharmaceutical leader with a market capitalization of $68.5 billion and an impressive gross profit margin of 72%, announced today that its investigational drug ...

Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK is nearing a $1bn deal to buy a US biotech developing a treatment for rare gastrointestinal tumours ...

Investing.com -- GSK Plc's CEO Emma Walmsley has expressed intentions to engage in more business deals, as the British pharmaceutical company intensifies its focus on cancer treatments.

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...